Previous 10 | Next 10 |
Tango Therapeutics (NASDAQ:TNGX) has appointed Marc Rudoltz as the company’s new Chief Medical Officer. An alumnus of the Massachusetts Institute of Technology (MIT) and SUNY-Upstate Medical University, Rudoltz has over 20 years of experience in leading clinical-stage drug develop...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 ...
If you're looking for stocks that can make big moves on a relatively predictable timeline, the biotechnology space has you covered. Hardly a day goes by where you don't see at least one stock from this industry rocket higher, or crash and burn. Right now, investors are waiting for n...
– Seventh Approval Worldwide for QINLOCK and First European Approval – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced t...
– DCC-3116 Shown to Inhibit EGFR and EGFR Family Inhibitor-induced Autophagy in Multiple EGFR-mutant Non-Small Cell Lung Cancer Cell Lines and Decrease Tumor Burden in Combination with Osimertinib and Afatinib in EGFR Mutant Xenograft Model – Deciphera Pharmace...
The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this event. For further details see: Deciphera Pharmaceuticals (DCPH) ESMO 2021Virtual Congress Presentation - Slideshow
– European Commission Decision Anticipated by the Fourth Quarter of 2021 – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announc...
– Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated Patients with Platinum-Resistant Ovarian Cancer (PROC) – – Pivotal Phase 3 Study of Rebastinib plus Paclitaxel in PROC Planned to Initiat...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...